Listed

Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 16:43 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-01-01 to 2016-03-31$5.5mus-gaap:Revenues
Selling, general and administrative3 months2016-01-01 to 2016-03-31$4.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-01-01 to 2016-03-31−$868.0kus-gaap:OperatingIncomeLoss
Income tax3 months2016-01-01 to 2016-03-31$19.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-01-01 to 2016-03-31−$1.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-01-01 to 2016-03-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2016-01-01 to 2016-03-31−$504.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2016-01-01 to 2016-03-31$177.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-03-31$3.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$9.1mus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$16.3mus-gaap:Assets
Current liabilitiesAt period end2016-03-31$6.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-03-31$13.3mus-gaap:Liabilities
Current portion of debtAt period end2016-03-31$3.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2016-03-31$3.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-16-009551. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.